Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

BACKGROUND Voriconazole is the therapy of choice for aspergillosis and a new treatment option for candidiasis. Liver disease, age, genetic polymorphism of the cytochrome CYP2C19, and comedications influence voriconazole metabolism. Large variations in voriconazole pharmacokinetics may be associated with decreased efficacy or with toxicity. METHODS This study was conducted to assess the utility of measuring voriconazole blood levels with individualized dose adjustments. RESULTS A total of 181 measurements with high-pressure liquid chromatography were performed during 2388 treatment days in 52 patients. A large variability in voriconazole trough blood levels was observed, ranging from <or=1 mg/L (the minimum inhibitory concentration at which, for most fungal pathogens, 90% of isolates are susceptible) in 25% of cases to >5.5 mg/L (a level possibly associated with toxicity) in 31% of cases. Lack of response to therapy was more frequent in patients with voriconazole levels <or=1 mg/L (6 [46%] of 13 patients, including 5 patients with aspergillosis, 4 of whom were treated orally with a median dosage of 6 mg/kg per day) than in those with voriconazole levels >1 mg/L (15 [12%] of 39 patients; P=.02). Blood levels >1 mg/L were reached after increasing the voriconazole dosage, with complete resolution of infection in all 6 cases. Among 16 patients with voriconazole trough blood levels >5.5 mg/L, 5 patients (31%) presented with an encephalopathy, including 4 patients who were treated intravenously with a median voriconazole dosage of 8 mg/kg per day, whereas none of the patients with levels <or=5.5 mg/L presented with neurological toxicity (P=.002). Comedication with omeprazole possibly contributed to voriconazole accumulation in 4 patients. In all cases, discontinuation of therapy resulted in prompt and complete neurological recovery. CONCLUSIONS Voriconazole therapeutic drug monitoring improves the efficacy and safety of therapy in severely ill patients with invasive mycoses.

[1]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. J. Linares,et al.  Susceptibility of Filamentous Fungi to Voriconazole Tested by Two Microdilution Methods , 2005, Journal of Clinical Microbiology.

[3]  C. A. Kauffman,et al.  Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Sugar,et al.  Efficacy of Voriconazole in Treatment of Murine Pulmonary Blastomycosis , 2001, Antimicrobial Agents and Chemotherapy.

[5]  B. Potoski,et al.  The safety of voriconazole. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. Andes,et al.  Pharmacology of Systemic Antifungal Agents , 2006 .

[7]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[8]  D. Schaer,et al.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.

[9]  N. Wood,et al.  Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.

[10]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  G. Drusano.  How does a patient maximally benefit from anti-infective chemotherapy? , 2004, Clinical Infectious Diseases.

[12]  E. Thiel,et al.  Improved outcome in central nervous system aspergillosis, using voriconazole treatment. , 2005, Blood.

[13]  J. Pochet,et al.  Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  W. Vogel,et al.  Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis , 2007, Antimicrobial Agents and Chemotherapy.

[16]  B. Keevil,et al.  Adverse reactions to voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Ghannoum,et al.  Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints , 2006, Journal of Clinical Microbiology.

[18]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  R. Grillot,et al.  In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. , 2005, International journal of antimicrobial agents.

[20]  P. Lugtenburg,et al.  Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. , 2006, The Journal of antimicrobial chemotherapy.

[21]  T. Buclin,et al.  Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods , 2006, Antimicrobial Agents and Chemotherapy.

[22]  K. Sepkowitz,et al.  Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[24]  M. Piens,et al.  Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[25]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[26]  L. Gordon,et al.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.

[27]  J. Mehta,et al.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.

[28]  N. Wood,et al.  Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients , 2002, Clinical pharmacology and therapeutics.

[29]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[30]  D. Pittet,et al.  Treatment options of invasive fungal infections in adults. , 2006, Swiss medical weekly.

[31]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  N. Wood,et al.  Safety of voriconazole and dose individualization. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Karlsson,et al.  Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.

[34]  C. Viscoli,et al.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial , 2005, The Lancet.

[35]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.